Olink Bioscience Introduces a New 92-protein Biomarker Panel
Complete the form below to unlock access to ALL audio articles.
Olink Bioscience has launched Proseek® Multiplex Oncology II96x96 a new human protein biomarker panel that targets the cancer research area. This is part of the on-going development of the Proseek platform, expanding the library of unique biomarkers available and complementing the existing panels directed against cardiovascular and inflammatory diseases.
With the launch of this new panel, Olink can now provide more than 350 unique protein biomarker assays, and this offering will be significantly expanded in early 2016 with a panel focused on the clinically important field of neurology.
Proseek Multiplex Oncology II96x96 will be an important tool in the search for new protein signatures (expression patterns based on the measurement of multiple proteins) that could be used to improve the understanding, prediction and prognosis of cancer, the discovery of new drug targets, and in the development of more effective and personalized therapy for future patients.
Cancer is still one of the major causes of death and continues to require massive global research efforts. Complementing and enhancing the valuable contributions made by extensive genome-based studies in the cancer field, the ability to discover and validate more protein biomarkers is likely to be increasingly important in addressing this huge healthcare challenge.
“Global healthcare has to move towards more effective strategies where the appropriate treatments are selected for the individuals who will respond best to a specific therapeutic option (often called personalized or precision medicine). This is clearly the future of medicine, but achieving it requires effective ways to identify and stratify the patients so that clinicians understand how they will respond to any given treatment. By rapidly and accurately measuring many protein biomarkers simultaneously from small volumes of patient samples, Proseek Multiplex has enormous potential to become a valuable tool in these exciting developments for future healthcare improvements. The real journey towards precision medicine is just beginning, and Olink plans to be the partner of choice for those driving this revolution, every step of the way” says Andrea Ballagi, VP Sales & Marketing at Olink Bioscience.
Product and technology information
Proseek Multiplex Oncology II96x96 offers high-throughput multiplex immunoassays that measure 92 cancer-related proteins across 96 samples simultaneously using only one microliter of serum, plasma, or almost any other type of biological sample. This panel replaces and improves on our successful Proseek Multiplex Oncology I v296x96 panel, offering 60 completely new oncology-focused biomarker assays. The composition of the panel was designed to maximize the number of useful oncology markers, as well as the overall performance of the assays. Using Proseek Multiplex, researchers can analyze thousands of samples per week, which greatly accelerates the speed of protein biomarker research.
Proseek Multiplex is based on the proprietary Proximity Extension Assay (PEA) technology developed by Olink Bioscience. PEA is a homogeneous assay that uses pairs of antibodies equipped with DNA reporter molecules which upon target binding give rise to new DNA amplicons, each ID-barcoding their respective antigens.
Cross-reactive events are not detected since the sequence design allows only the correctly matched antibody pairs to give rise to a signal. The amplicons are subsequently quantified by high throughput real-time PCR. This dual recognition, DNA-coupled method provides exceptional readout specificity and enables Proseek Multiplex to achieve a combination of high multiplexing level and data quality that cannot be matched using standard immunoassay techniques.
